Fig. EV5

TTLL6 also tunes p60-Katanin-driven pMN axon development. (A) Immunolabelling of pMN axons in 26-hpf embryos injected with MOCtl (n = 32), MOp60Kat/1.3pmol (n = 32) or co-injected with MOp60Kat/1.3pmol and 120 pg of human KATNA1 transcripts (MOp60Kat/1.3pmol + mRNAKATNA1, n = 32) using Znp-1 antibody. (B) Mean number of pMN axon branches per embryo analysed in the panel-A embryo set. (C) Immunodetection of pMN axons with Znp-1 antibody in 26-hpf embryos injected with MOCtl (n = 19), MOTTLL6 (n = 22), MOTTLL11 (n = 19) morpholinos or co-injected with MOTTLL6 or MOTTLL11 and mouse TTLL6 or TTLL11 mRNA (MOTTLL6 + mRNATTLL6, n = 20; MOTTLL6 + mRNATTLL11, n = 21; MOTTLL11 + mRNATTLL11, n = 19; MOTTLL11 + mRNATTLL6, n = 18). (D, E) Mean number of CaP pMN branches (D) and truncated CaP axons per embryo analysed in the panel-C embryo set. (F) Immunostaining of pMN axons with Znp-1 antibody in 26-hpf embryos injected with MOCtl, (n = 20), MOp60Kat/1.3pmol (n = 21) or co-injected with MOp60Kat/1.3pmol and mouse TTLL6 (MOp60Kat/1.3pmol + mRNATTLL6, n = 19) or TTLL11 mRNA (MOp60Kat/1.3pmol + mRNATTLL11, n = 16). (G) Mean number of CaP pMN branches per embryo analysed in the panel-F embryo set. (A, C, F) Arrows and asterisk respectively indicate hyper-branched and truncated ventrally projecting pMN CaP axons. Empty arrowheads indicate normal dorsally projecting pMN MiP axons. Scale bars: 25 μm. (B, D, E, G) Non-blind quantifications were performed on 24 spinal hemisegments located around the yolk tube per embryo. Analysed larvae were pooled from three independent experiments. Violin Plots; horizontal bars indicate the median ± the 1st and 3rd quartiles. One-way ANOVA test with Bonferroni’s post test (D, G) or Kruskal–Wallis ANOVA test with Dunn’s post test (B, E). P values are displayed on graphs. Source data are available online for this figure.